Skip to Main Content

Advertisement

Skip Nav Destination

Issue Archive

Table of Contents

Inside Blood

CLINICAL TRIALS

It is barely more than a decade since Toll-like receptors (TLRs) were linked to the innate immune response.1  Yet substantial data are now emerging that indicate that TLR agonists may have a significant role in the therapy of mycosis fungoides and Sezary syndrome.2,3 

GENE THERAPY

The use of gene transfer techniques to introduce TCR α/β genes that confer specificity for a target antigen offers the opportunity to produce large numbers of cancer-specific T cells for adoptive therapy.1  In this issue of Blood, Nagai and colleagues examine the feasibility of adoptive therapy using lymphocytes genetically engineered to express the T-cell receptor (TCR) for the leukemia-associated antigen Aurora kinase A (AURKA).2 

MYELOID NEOPLASIA

In this issue of Blood, Frisch and colleagues identify an unexpected effect of leukemia cells: alterations in bone homeostasis within the bone marrow hematopoietic microenvironment.1 

THROMBOSIS & HEMOSTASIS

In this issue of Blood, Milanov and colleagues demonstrate that a Factor IX (FIX) variant that does not require activated Factor VIII (FVIIIa) for activity induces coagulation in hemophilia A mice with FVIII inhibitors.1  This protein might be developed as a bypass agent.

VASCULAR BIOLOGY

Segal and colleagues in this issue of Blood report their findings about an additional new function for the hormone relaxin: turning on bone marrow–derived endothelial progenitor cells to sites of neoangiogenesis.1 

Blood Work

Plenary Paper

PLENARY PAPER

Review Article

Blood Consult

Clinical Trials and Observations

Gene Therapy

Hematopoiesis and Stem Cells

Immunobiology

Lymphoid Neoplasia

Myeloid Neoplasia

Phagocytes, Granulocytes, and Myelopoiesis

Platelets and Thrombopoiesis

Red Cells, Iron, and Erythropoiesis

Thrombosis and Hemostasis

Transplantation

Vascular Biology

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X